HYDROCHLOROTHIAZIDE W Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Hydrochlorothiazide W, and what generic alternatives are available?
Hydrochlorothiazide W is a drug marketed by Watson Labs, Ivax Sub Teva Pharms, Pharmeral, and Roxane. and is included in fifteen NDAs.
The generic ingredient in HYDROCHLOROTHIAZIDE W is hydralazine hydrochloride; hydrochlorothiazide; reserpine. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide; reserpine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for HYDROCHLOROTHIAZIDE W?
- What are the global sales for HYDROCHLOROTHIAZIDE W?
- What is Average Wholesale Price for HYDROCHLOROTHIAZIDE W?
Summary for HYDROCHLOROTHIAZIDE W
| US Patents: | 0 |
| Applicants: | 4 |
| NDAs: | 15 |
| DailyMed Link: | HYDROCHLOROTHIAZIDE W at DailyMed |
US Patents and Regulatory Information for HYDROCHLOROTHIAZIDE W
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Watson Labs | HYDROCHLOROTHIAZIDE W/ HYDRALAZINE | hydralazine hydrochloride; hydrochlorothiazide | TABLET;ORAL | 085373-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pharmeral | HYDROCHLOROTHIAZIDE W/ RESERPINE | hydrochlorothiazide; reserpine | TABLET;ORAL | 085420-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ivax Sub Teva Pharms | HYDROCHLOROTHIAZIDE W/ RESERPINE | hydrochlorothiazide; reserpine | TABLET;ORAL | 083568-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
